Route 92 Medical Raises Financing to Support Neurovascular Intervention Portfolio

April 7, 2026—Route 92 Medical, Inc., a privately held medical technology company focused on neurovascular intervention, announced a $50 million growth financing.

According to Route 92, the proceeds from the financing will be used to help accelerate the company’s global commercial expansion, advance clinical evidence to support broader adoption of its neurovascular procedural approach, and invest in continued product innovation across its platform.

New investor Sectoral Asset Management joined lead investor Novo Holdings and returning investors US Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group in the financing round, stated Route 92 Medical.

As outlined in the press release, the company’s neurovascular portfolio includes the HiPoint reperfusion system featuring the Monopoint approach. The system is a super-bore aspiration catheter with a mono-axial procedural approach and an 0.088-inch inner diameter.

In May 2025, Route 92 Medical announced both FDA 510(k) clearance for the HiPoint reperfusion system and results from its pivotal SUMMIT MAX randomized controlled trial, which was conducted to provide clinical evidence to support the application for FDA clearance.

Additionally, Route 92’s suite of stroke treatment solutions includes the HiPoint 70 reperfusion system, FreeClimb 70 reperfusion system, FreeClimb 54 reperfusion system, and the FreeClimb 88 access system.